MENU
BBP
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BBP
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BBP with price predictions
Oct 19, 2026

Momentum Indicator for BBP turns negative, indicating new downward trend

BBP saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 78 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

BBP moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BBP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for BBP entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 61 cases where BBP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in 280 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

BBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus Biotech ETF (BBP) ETF is 18.88B. The market cap for tickers in the group ranges from 567.12M to 229.74B. AMGN holds the highest valuation in this group at 229.74B. The lowest valued company is PHAT at 567.12M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus Biotech ETF (BBP) ETF was -1%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was 17%. LQDA experienced the highest price growth at 23%, while SNDX experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Virtus Biotech ETF (BBP) ETF was 27%. For the same stocks of the ETF, the average monthly volume growth was -58% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 55
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 69
Seasonality Score: 24 (-100 ... +100)